Glenmark Pharmaceuticals: Board Meeting Outcome for Unaudited Financial Results (Standalone And Consolidated) For The Third Quarter And Nine Months Ended 31St December 2025

Pursuant to Regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we wish to inform that the Board at its meeting held today has approved the unaudited financial results for the Third Quarter and Nine Months ended 31st December 2025.